Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Champions Oncology's Enterprise Value is $89.93 Mil.
Champions Oncology's EBIT for the trailing twelve months (TTM) ended in Jan. 2026 was $-2.22 Mil. Therefore, Champions Oncology's EV-to-EBIT ratio for today is -40.45.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Champions Oncology's Enterprise Value is $89.93 Mil.
Champions Oncology's EBITDA for the trailing twelve months (TTM) ended in Jan. 2026 was $-0.77 Mil. Therefore, Champions Oncology's EV-to-EBITDA ratio for today is -116.34.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Champions Oncology's Enterprise Value is $89.93 Mil.
Champions Oncology's Revenue for the trailing twelve months (TTM) ended in Jan. 2026 was $57.94 Mil. Therefore, Champions Oncology's EV-to-Revenue ratio for today is 1.55.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Champions Oncology (NAS:CSBR) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Champions Oncology's current Enterprise Value is $89.93 Mil.
Champions Oncology's EBIT for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.22 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Champions Oncology's current Enterprise Value is $89.93 Mil.
Champions Oncology's EBITDA for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.77 Mil.
Champions Oncology's current Enterprise Value is $89.93 Mil.
Champions Oncology's Revenue for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $57.94 Mil.
Champions Oncology's current Enterprise Value is $89.93 Mil.
Champions Oncology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.39 Mil.
Champions Oncology's current Enterprise Value is $89.93 Mil.
Champions Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology Enterprise Value Related Terms
Champions Oncology Enterprise Value Historical Data
* Premium members only.
The historical data trend for Champions Oncology's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBR vs ANVS, HYFT, GANX: Enterprise Value Comparison
For the Biotechnology subindustry, Champions Oncology's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Champions Oncology's Enterprise Value for the fiscal year that ended in Apr. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (CSBR) has a Enterprise Value of $89.93 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Champions Oncology and its competitors.
Is Champions Oncology's Enterprise Value too high?
Champions Oncology's current Enterprise Value is $89.93 Mil. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Enterprise Value compare to ANVS and HYFT?
Champions Oncology's Enterprise Value of $89.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Champions Oncology and its competitors. Champions Oncology's current Enterprise Value is $89.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.63 — trading 0.2% above its estimated fair value. The current Enterprise Value is $89.93 Mil. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Enterprise Value is $89.93 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be overvalued.
The current stock price of $6.63 is trading 0.2% above its estimated GF Value™ of $6.62.
GuruFocus considers Champions Oncology to be Fairly Valued.
Key valuation signals for CSBR:
Enterprise Value: $89.93 Mil
GF Value™: $6.62 vs. price of $6.63 (0.2% above fair value)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
